Quality of life in patients with prostatic carcinoma: A review and results of a study in N+ disease Prostate-specific antigen as predictor of quality of life

Andel, George van; Kurth, K. H.; Haes, J.C.J.M. de

doi:10.1007/bf00941993

Cited by 17 publications

(4 citation statements)

References 33 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HRQoL was assessed longitudinally using the self‐administered Functional Assessment of Cancer Therapy – Prostate (FACT‐P; v4) [16,17]. First the QoL was assessed within the 3 days before enrolment and then every 3 weeks; during the follow‐up QoL, was assessed every month until progression or administration of further therapy.…”

Section: Methodsmentioning

confidence: 99%

“…The pain response (PPI questionnaire [15] and AS) and PSA response were evaluated compared to baseline. The QoL evaluation was extracted from the FACT‐P questionnaire [16,17] on all patients enrolled for whom at least one QoL questionnaire had been considered evaluable for the analysis. Descriptive statistics were used to report the changes from baseline for continuous variables.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone

et al. 2008

View full text Add to dashboard Cite

PATIENTS AND METHODSThirty patients from four centres were enrolled in the study; all had had previous MP for symptomatic, metastatic HRPC and all had castrate levels of testosterone maintained during therapy. RESULTSAt enrolment, the median age was 69 years, the mean PSA level was 324 ng/dL, and 86% of patients reported pain. There was a PSA response in 57% of the men and a reduction in pain in > 60%; the overall QoL was maintained. There were four cases of febrile neutropenia and two treatment-related deaths. The median progression-free and overall survival were 5 and 15 months, respectively. CONCLUSIONDocetaxel was associated with high rates of PSA and pain response in this study. Nonhaematological toxicity was similar to that during first-line treatment, but rates of febrile neutropenia and toxic death appeared to be slightly higher. In selected patients with progressive metastatic HRPC previously treated with mitoxantrone, docetaxel appears to be a beneficial therapeutic option. KEYWORDSprostatic neoplasms, drug therapy, docetaxel, mitoxantrone, phase II, pain Study Type -Therapy (individual cohort study) Level of Evidence 2c OBJECTIVETo investigate the use of docetaxel 75 mg/m 2 intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormonerefractory prostate cancer (HRPC) progressing after first-line mitoxantrone/ prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone

et al. 2008

View full text Add to dashboard Cite

show abstract

“…For reviews of just the physical symptoms associated with prostate cancer and its treatments, we refer the reader to several excellent articles (see Altwein et al, 1997;Middleton et al, 1995;Shipley et al, 1994;Wasson et al, 1993). Furthermore, unlike other reviews (see Herr, 1997;Van Andel et al, 1997) we chose to exclude studies that did not use validated measures of HRQoL. Finally, we review here only studies that make inferential statistical comparisons.…”

Section: Prostate Cancer and Hrqolmentioning

confidence: 99%

Prostate cancer and health‐related quality of life: a review of the literature

2002

View full text Add to dashboard Cite

SUMMARYWith the established effectiveness of diverse treatments for prostate cancer, identification of the physical and psychosocial consequences of the disease and various treatments becomes critical. We review the literature on the effects of prostate cancer and its treatment on health-related quality of life (HRQoL). Studies show that prostate cancer and its treatment affect both disease-specific HRQoL (i.e. urinary, sexual, and bowel function) as well as general HRQoL (i.e. energy/vitality, performance in physical and social roles). Yet, these effects appear to differ across stage of disease and type of treatment. We outline evidence from three sources: (1) studies that compare men with the disease with an age-matched sample of men without the disease, (2) studies that assess men with the disease across time, and (3) cross-sectional studies that highlight predictors of HRQoL. Future research directions are discussed.

show abstract

“…Kurian, Leader [9] found that prostate cancer patients with younger age had better QOL than older patients. Increase in PSA levels also reduced QOL [10].…”

Section: Introductionmentioning

confidence: 94%

The Quality of Life for Patients with Early Stage Prostate Cancer in Brachytherapy and Radical Prostatectomy Surgery

Li¹

2019

Nur Primary Care

View full text Add to dashboard Cite

The purpose of the study was to evaluate the quality of life (QOL) after open radical prostatectomy (ORP), laparoscopic radical prostatectomy (LRP) and brachytherapy (BT). Methods: A longitudinal, descriptive, comparative design was conducted in southern Taiwan. A total of 49 prostate cancer patients treated with OPR, LRP and BT were recruited in this study. Data were completed at the following five time points: before treatment/baseline and at 1, 2, 3, and 8 months after treatment. The European Organization on Research and Treatment of Cancer quality of life (EORTC QLQ-C30) was used to assess the QOL in functional scales and global health status. The EROCT Prostate Cancer Module (QLQ-RP25) was used to measure the QOL in urinary symptoms. The generalized estimating equation (GEE) was used to analyze the different QOL values after three treatments within 8 months. Results: There were no significant differences in the functional scales and global health status quality of life between the OPR and BT groups. Additionally, there were no significant differences between the LRP and BT groups in the functional scales and global health status. The QOL in urinary symptoms was worse in the ORP group at 1, 2, and 3 months, and it was worse in the LRP group at 1, 2, 3, and 8 months when the reference group was BT with the baseline time point. Conclusion: Prostate cancer patients had similar QOL in functional scales and global health after three treatments. However, urinary symptoms were worse in the ORP and LRP groups of patients than in the BT groups.

show abstract

Quality of life in patients with prostatic carcinoma: A review and results of a study in N+ disease Prostate-specific antigen as predictor of quality of life

Cited by 17 publications

References 33 publications

The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone

The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone

Prostate cancer and health‐related quality of life: a review of the literature

The Quality of Life for Patients with Early Stage Prostate Cancer in Brachytherapy and Radical Prostatectomy Surgery

Contact Info

Product

Resources

About